

# Ash A Alizadeh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4862871/publications.pdf>

Version: 2024-02-01

232  
papers

52,916  
citations

8181

76  
h-index

2385

198  
g-index

238  
all docs

238  
docs citations

238  
times ranked

54576  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. <i>Blood Cancer Discovery</i> , 2022, 3, 5-15.	5.0	25
2	SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool. <i>Journal of Geriatric Oncology</i> , 2022, 13, 258-264.	1.0	9
3	CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity. <i>Blood Cancer Discovery</i> , 2022, 3, 95-102.	5.0	36
4	Inferring gene expression from cell-free DNA fragmentation profiles. <i>Nature Biotechnology</i> , 2022, 40, 585-597.	17.5	63
5	Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. <i>Cancers</i> , 2022, 14, 2479.	3.7	3
6	Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Cancer Research</i> , 2022, 82, 2838-2847.	0.9	14
7	Phased variants improve DLBCL minimal residual disease detection at the end of therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7565-7565.	1.6	1
8	Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8518-8518.	1.6	4
9	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. <i>Nature Biotechnology</i> , 2021, 39, 1537-1547.	17.5	151
10	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2605-2616.	1.6	37
11	A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2016-2025.	4.1	15
12	The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1422-1437.e10.	16.8	102
13	Atlas of clinically distinct cell states and ecosystems across human solid tumors. <i>Cell</i> , 2021, 184, 5482-5496.e28.	28.9	116
14	Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 233-233.	1.4	6
15	Tumor-Confirmed Follicular Lymphoma Mutations Are Detectable in Peripheral Blood Years Prior to Clinical Diagnosis. <i>Blood</i> , 2021, 138, 709-709.	1.4	1
16	Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma. <i>Blood</i> , 2021, 138, 6-6.	1.4	15
17	Noninvasive Cell-of-Origin Classification of Diffuse Large B-Cell Lymphoma Using Inferred Gene Expression from Cell-Free DNA Sequencing. <i>Blood</i> , 2021, 138, 37-37.	1.4	0
18	Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 3519-3519.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. <i>Cancer Discovery</i> , 2021, 11, 2968-2986.	9.4	116
20	Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2064-2064.	1.4	0
21	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	1.3	147
22	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	9.4	93
23	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
24	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	26
25	Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models. <i>Blood Advances</i> , 2020, 4, 4451-4462.	5.2	8
26	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6176-6186.	7.0	13
27	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. <i>Nature Communications</i> , 2020, 11, 6410.	12.8	66
28	A mathematical model of ctDNA shedding predicts tumor detection size. <i>Science Advances</i> , 2020, 6, .	10.3	105
29	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	27.8	379
30	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	13.2	201
31	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, 650.	7.1	696
32	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	7.0	74
33	Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. <i>Methods in Molecular Biology</i> , 2020, 2117, 135-157.	0.9	249
34	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). <i>Blood</i> , 2020, 136, 49-50.	1.4	3
35	Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage. <i>Blood</i> , 2020, 136, 30-31.	1.4	2
36	Circulating tumor DNA in Genetic Profiling and Monitoring of Pediatric Hodgkin Lymphoma. , 2020, 232, .		0

#	ARTICLE	IF	CITATIONS
37	Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 27-28.	1.4	1
38	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	28.9	138
39	Targetable genetic alterations of <i>TCF4</i> ( <i>E2-2</i> ) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	51
40	Predicting HLA class II antigen presentation through integrated deep learning. <i>Nature Biotechnology</i> , 2019, 37, 1332-1343.	17.5	218
41	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	17.5	2,396
42	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	1.6	2
43	Early Detection of Post-Transplant Lymphoproliferative Disorder Using Circulating Tumor DNA. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S12-S13.	0.6	1
44	P2.05-01 Broad Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S747-S748.	1.1	0
45	Functional significance of U2AF1 S34F mutations in lung adenocarcinomas. <i>Nature Communications</i> , 2019, 10, 5712.	12.8	27
46	Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA. <i>Cancer Discovery</i> , 2019, 9, 500-509.	9.4	143
47	B-cell lymphomas present immunoglobulin neoantigens. <i>Blood</i> , 2019, 133, 878-881.	1.4	36
48	Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucele Therapy. <i>Blood</i> , 2019, 134, 550-550.	1.4	13
49	An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019, 134, 655-655.	1.4	4
50	Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA. <i>Blood</i> , 2019, 134, 552-552.	1.4	5
51	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , 2019, 134, 1600-1600.	1.4	3
52	Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling. <i>Blood</i> , 2019, 134, 551-551.	1.4	9
53	ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2547-2547.	1.6	1
54	Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Moller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. <i>Blood</i> . 2011;117(8):2423-2432.. <i>Blood</i> , 2019, 134, 658-658.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 491-491.	1.4	0
56	Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment. <i>Blood</i> , 2019, 134, 2799-2799.	1.4	1
57	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2018, 24, 2688-2699.	7.0	45
58	Genomic feature selection by coverage design optimization. <i>Journal of Applied Statistics</i> , 2018, 45, 2658-2676.	1.3	1
59	Profiling Tumor Infiltrating Immune Cells with CIBERSORT. <i>Methods in Molecular Biology</i> , 2018, 1711, 243-259.	0.9	1,936
60	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	1.6	313
61	Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003004.	1.2	10
62	(OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, e1-e2.	0.8	0
63	Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. <i>Blood</i> , 2018, 132, 672-672.	1.4	4
64	Early detection of post-transplant lymphoproliferative disorder using circulating tumor DNA. <i>Journal of Clinical Oncology</i> , 2018, 36, 7572-7572.	1.6	1
65	Post-transplant head and neck cancers: A prospective analysis of clinical factors for risk stratification. <i>Journal of Clinical Oncology</i> , 2018, 36, e18051-e18051.	1.6	0
66	Abstract B49: Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq. , 2018, , .		0
67	Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. <i>Blood</i> , 2018, 132, 2861-2861.	1.4	0
68	(S012) Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E4.	0.8	0
69	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , 2017, 130, 440-452.	1.4	66
70	Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. <i>Blood</i> , 2017, 129, 2645-2656.	1.4	84
71	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. <i>Nature</i> , 2017, 543, 723-727.	27.8	232
72	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017, 129, 759-770.	1.4	69

#	ARTICLE	IF	CITATIONS
73	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	9.4	701
74	PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 207-208.	1.7	1
75	Role of <i>KEAP1</i> and <i>NRF2</i> and <i>TP53</i> Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. <i>Cancer Discovery</i> , 2017, 7, 86-101.	9.4	239
76	MA 13.01 Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1851.	1.1	0
77	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2017, 148, 465-476.	0.7	7
78	Data normalization considerations for digital tumor dissection. <i>Genome Biology</i> , 2017, 18, 128.	8.8	25
79	Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3591.	1.6	27
80	Circulating tumor DNA analysis for outcome prediction in localized esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4055-4055.	1.6	3
81	Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8519-8519.	1.6	3
82	Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7538-7538.	1.6	0
83	Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7507-7507.	1.6	4
84	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. <i>Blood</i> , 2017, 130, 826-826.	1.4	4
85	High-throughput genomic profiling of tumor-infiltrating leukocytes. <i>Current Opinion in Immunology</i> , 2016, 41, 77-84.	5.5	43
86	Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA. , 2016, , .		0
87	A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma. <i>Annals of Oncology</i> , 2016, 27, vi393.	1.2	4
88	CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S41-S42.	0.8	3
89	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016, 8, 364ra155.	12.4	348
90	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	12.8	520

#	ARTICLE	IF	CITATIONS
91	Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology, 2016, 34, 547-555.	17.5	837
92	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 1089-1089.	1.4	8
93	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. Blood, 2016, 128, 1752-1752.	1.4	8
94	Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. Blood, 2016, 128, 181-181.	1.4	56
95	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2686-2686.	1.4	1
96	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. Journal of Clinical Oncology, 2016, 34, 7511-7511.	1.6	3
97	Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.. Journal of Clinical Oncology, 2016, 34, 9000-9000.	1.6	2
98	Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.. Journal of Clinical Oncology, 2016, 34, e20500-e20500.	1.6	1
99	Noninvasive molecular subtyping and risk stratification of DLBCL.. Journal of Clinical Oncology, 2016, 34, 7554-7554.	1.6	2
100	Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens. Blood, 2016, 128, 915-915.	1.4	0
101	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 2930-2930.	1.4	8
102	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. Blood, 2016, 128, 4107-4107.	1.4	1
103	Analysis of Circulating Tumor DNA in Esophageal Carcinoma Patients Treated With Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, S104-S105.	0.8	1
104	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1116-25.	7.1	307
105	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	30.7	604
106	Organocatalytic removal of formaldehyde adducts from RNA and DNA bases. Nature Chemistry, 2015, 7, 752-758.	13.6	41
107	Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Seminars in Radiation Oncology, 2015, 25, 305-312.	2.2	97
108	The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine, 2015, 21, 938-945.	30.7	2,505

#	ARTICLE	IF	CITATIONS
109	Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Review of Molecular Diagnostics, 2015, 15, 715-719.	3.1	75
110	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	1.4	270
111	Robust enumeration of cell subsets from tissue expression profiles. Nature Methods, 2015, 12, 453-457.	19.0	8,460
112	Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2015, 107, djv211.	6.3	64
113	Abstract P5-04-03: Deconvoluting immune cell populations using <i>in silico</i> flow cytometry™ with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC. , 2015, , .		3
114	Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 114-114.	1.4	10
115	Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 130-130.	1.4	9
116	Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging. PLoS ONE, 2015, 10, e0133627.	2.5	90
117	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8539-8539.	1.6	0
118	Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers. Cancer Research, 2015, 75, PR09-PR09.	0.9	3
119	Hit-and-run lymphomagenesis by the Bcl6 oncogene. Cell Cycle, 2014, 13, 1831-1832.	2.6	6
120	Common progenitor cells in mature B-cell malignancies. Current Opinion in Hematology, 2014, 21, 333-340.	2.5	17
121	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 2014, 20, 548-554.	30.7	1,771
122	Mixed Phenotype Acute Leukemia. American Journal of Clinical Pathology, 2014, 142, 803-808.	0.7	62
123	FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics, 2014, 30, 3390-3393.	4.1	212
124	Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. International Journal of Radiation Oncology Biology Physics, 2014, 90, S75.	0.8	1
125	A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates. Journal of the American Statistical Association, 2014, 109, 1517-1532.	3.1	227
126	Active Idiomatic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 1797-1803.	1.6	75



#	ARTICLE	IF	CITATIONS
127	Tumor antigen discovery through translation of the cancer genome. <i>Immunologic Research</i> , 2014, 58, 292-299.	2.9	13
128	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , 2014, 5, 3904.	12.8	73
129	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. <i>Journal of Clinical Oncology</i> , 2014, 32, 8504-8504.	1.6	0
130	Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. <i>Journal of Clinical Oncology</i> , 2014, 32, 11016-11016.	1.6	0
131	Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. <i>Clinical Immunology</i> , 2013, 148, 124-135.	3.2	13
132	Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study. <i>Leukemia and Lymphoma</i> , 2013, 54, 743-751.	1.3	12
133	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. <i>Blood</i> , 2013, 121, 1367-1376.	1.4	147
134	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. <i>Blood</i> , 2013, 121, 1604-1611.	1.4	279
135	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. <i>Nature Communications</i> , 2013, 4, 1338.	12.8	37
136	Utility in prognostic value added by molecular profiles for diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 3052-3054.	1.4	2
137	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013, 122, 1768-1768.	1.4	2
138	Abstract A74: The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. , 2013, , .		0
139	First Isolation of <i>Cryptococcus uzbekistanensis</i> from an Immunocompromised Patient with Lymphoma. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1125-1127.	3.9	15
140	The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. <i>Journal of Experimental Medicine</i> , 2012, 209, 1427-1435.	8.5	140
141	Three differentiation states risk-stratify bladder cancer into distinct subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2078-2083.	7.1	232
142	Treatment advances have not improved the early death rate in acute promyelocytic leukemia. <i>Haematologica</i> , 2012, 97, 133-136.	3.5	122
143	Self-antigen recognition by follicular lymphoma B-cell receptors. <i>Blood</i> , 2012, 120, 4182-4190.	1.4	81
144	A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1299-1305.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S713.	0.8	0
146	CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas. <i>American Journal of Pathology</i> , 2012, 181, 795-803.	3.8	52
147	Correction: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. <i>Arthritis Research and Therapy</i> , 2012, 14, 403.	3.5	12
148	Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. <i>Arthritis Research and Therapy</i> , 2012, 14, R25.	3.5	162
149	The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6662-6667.	7.1	1,255
150	Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 957-960.	4.1	22
151	Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma. <i>PLoS ONE</i> , 2012, 7, e46117.	2.5	18
152	Genome-Wide Characterization of Human Hematopoietic Progenitor Cell Heterogeneity by Expression Profiling of Single Cells: A Pilot Study. <i>Blood</i> , 2012, 120, 1231-1231.	1.4	0
153	Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. <i>Blood</i> , 2012, 120, 3713-3713.	1.4	0
154	Systematic Deconvolution of Hematolymphoid Tumor Transcriptomes Reveals Infiltrating Immune Cell Signatures Related to Survival. <i>Blood</i> , 2012, 120, 2390-2390.	1.4	3
155	Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma. <i>Blood</i> , 2012, 120, 148-148.	1.4	0
156	Identification of Candidate Transcriptional Biomarkers Associated with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4190-4190.	1.4	0
157	The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. <i>Blood</i> , 2012, 120, 790-790.	1.4	1
158	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. <i>Blood</i> , 2011, 117, 2423-2432.	1.4	195
159	Surprise! HSC Are Aberrant in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2011, 20, 135-136.	16.8	15
160	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	1.4	175
161	A proteomic approach for the identification of novel lysine methyltransferase substrates. <i>Epigenetics and Chromatin</i> , 2011, 4, 19.	3.9	55
162	Utility of positron emission tomography scans in mantle cell lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 841-845.	4.1	55

#	ARTICLE	IF	CITATIONS
163	Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. <i>Hematological Oncology</i> , 2011, 29, 157-160.	1.7	25
164	A few good genes. <i>Cell Cycle</i> , 2011, 10, 3615-3616.	2.6	3
165	Leukemic Stem Cell Gene Expression Signature and Clinical Outcomes in Acute Myeloid Leukemia—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1094.	7.4	0
166	Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2011, 71, 1374-1384.	0.9	318
167	Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5009-5014.	7.1	248
168	HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation. <i>Blood</i> , 2011, 118, 584-584.	1.4	1
169	A Multicenter Study Evaluating the Efficacy and Safety of Bendamustine in the Treatment of Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 4940-4940.	1.4	0
170	Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia. <i>Blood</i> , 2011, 118, 2552-2552.	1.4	0
171	Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. <i>American Journal of Hematology</i> , 2010, 85, 877-881.	4.1	37
172	Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). <i>Leukemia Research</i> , 2010, 34, 594-597.	0.8	29
173	B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12747-12754.	7.1	143
174	Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2706.	7.4	339
175	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. <i>Cell</i> , 2010, 142, 699-713.	28.9	894
176	Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47. <i>Science Translational Medicine</i> , 2010, 2, 63ra94.	12.4	591
177	Expression profiles of adult T-cell leukemia lymphoma and associations with clinical responses to zidovudine and interferon $\gamma$ . <i>Leukemia and Lymphoma</i> , 2010, 51, 1200-1216.	1.3	23
178	NF- $\kappa$ B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome. <i>Blood</i> , 2010, 116, 144-144.	1.4	2
179	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010, 116, 4742-4742.	1.4	3
180	Abstract PR5: Prediction of survival in diffuse large B-cell lymphoma based on the expression of two genes integrating tumor and microenvironment. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
181	Self-Antigen Recognition by the B Cell Receptors of Follicular Lymphoma. <i>Blood</i> , 2010, 116, 4124-4124.	1.4	0
182	A Novel Missense Mutation In An MDS Patient and Effects on TET2 mRNA Expression and Clinical Outcomes. <i>Blood</i> , 2010, 116, 1889-1889.	1.4	0
183	Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. <i>Blood</i> , 2010, 116, 3134-3134.	1.4	0
184	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. <i>Blood</i> , 2010, 116, 2006-2006.	1.4	0
185	Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2009, 360, 2794-2795.	27.0	19
186	CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. <i>Cell</i> , 2009, 138, 286-299.	28.9	1,371
187	A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. <i>Blood</i> , 2009, 114, 3158-3166.	1.4	52
188	Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. <i>Blood</i> , 2009, 114, 3431-3438.	1.4	121
189	Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.. <i>Blood</i> , 2009, 114, 1015-1015.	1.4	6
190	Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.. <i>Blood</i> , 2009, 114, 2716-2716.	1.4	1
191	A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling.. <i>Blood</i> , 2009, 114, 759-759.	1.4	14
192	Therapeutic Potential of Anti-CD137 Antibody in Lymphoma.. <i>Blood</i> , 2009, 114, 722-722.	1.4	1
193	Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).. <i>Blood</i> , 2009, 114, 1617-1617.	1.4	1
194	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. <i>Blood</i> , 2009, 114, 622-622.	1.4	2
195	Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 2951-2951.	1.4	0
196	Abstract CN07-03: CD47 is an adverse prognostic factor and therapeutic antibody target on human AML stem cells. , 2009, , .		2
197	Double trouble in follicular lymphoma: A rare and unusual synergy of oncogenes in the germinal center. <i>Leukemia and Lymphoma</i> , 2008, 49, 377-380.	1.3	1
198	CD47 Is An Independent Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells. <i>Blood</i> , 2008, 112, 766-766.	1.4	1

#	ARTICLE	IF	CITATIONS
199	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. <i>Blood</i> , 2008, 112, 3769-3769.	1.4	0
200	Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 899-909.	0.3	25
201	Diagnosis of a Critical Respiratory Illness Caused by Human Metapneumovirus by Use of a Pan-Virus Microarray. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2340-2343.	3.9	67
202	Cell-type specific gene expression profiles of leukocytes in human peripheral blood. <i>BMC Genomics</i> , 2006, 7, 115.	2.8	275
203	Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. <i>Blood</i> , 2005, 105, 2924-2932.	1.4	63
204	Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds. <i>PLoS Biology</i> , 2004, 2, e7.	5.6	824
205	AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. <i>Leukemia</i> , 2004, 18, 1775-1779.	7.2	70
206	Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes. <i>New England Journal of Medicine</i> , 2004, 350, 1828-1837.	27.0	874
207	Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. <i>Lancet, The</i> , 2004, 363, 203-209.	13.7	378
208	Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. <i>Blood</i> , 2004, 104, 1428-1434.	1.4	122
209	Rheumatoid arthritis is a heterogeneous disease: Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. <i>Arthritis and Rheumatism</i> , 2003, 48, 2132-2145.	6.7	418
210	Individuality and variation in gene expression patterns in human blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1896-1901.	7.1	723
211	SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. <i>Nucleic Acids Research</i> , 2003, 31, 219-223.	14.5	376
212	T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene Expression. <i>PLoS Biology</i> , 2003, 1, e53.	5.6	88
213	HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 433-440.	1.4	84
214	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. <i>Blood</i> , 2003, 101, 3109-3117.	1.4	212
215	Stereotyped and specific gene expression programs in human innate immune responses to bacteria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 972-977.	7.1	371
216	Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8886-8891.	7.1	204

#	ARTICLE	IF	CITATIONS
217	Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11796-11801.	7.1	300
218	In Vivo Regulation of Human Skeletal Muscle Gene Expression by Thyroid Hormone. Genome Research, 2002, 12, 281-291.	5.5	143
219	The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood, 2002, 99, 2285-2290.	1.4	266
220	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. American Journal of Pathology, 2002, 161, 1557-1565.	3.8	194
221	Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplantation Proceedings, 2001, 33, 297-298.	0.6	23
222	Towards a novel classification of human malignancies based on gene expression patterns. Journal of Pathology, 2001, 195, 41-52.	4.5	265
223	Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia. Journal of Experimental Medicine, 2001, 194, 1639-1648.	8.5	978
224	Examining the Living Genome in Health and Disease With DNA Microarrays. JAMA - Journal of the American Medical Association, 2000, 283, 2298.	7.4	17
225	Genomic-scale gene expression profiling of normal and malignant immune cells. Current Opinion in Immunology, 2000, 12, 219-225.	5.5	113
226	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403, 503-511.	27.8	8,977
227	Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10209-10213.	7.1	220
228	'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biology, 2000, 1, research0003.1.	9.6	392
229	Examining the Living Genome in Health and Disease With DNA Microarrays. JAMA - Journal of the American Medical Association, 2000, 283, 2298-2299.	7.4	9
230	Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genetics, 1999, 23, 41-46.	21.4	928
231	The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 71-78.	1.1	218
232	Probing lymphocyte biology by genomic-scale gene expression analysis. Journal of Clinical Immunology, 1998, 18, 373-379.	3.8	96